Inhibiting NR5A2 targets stemness in pancreatic cancer by disrupting SOX2/MYC signaling and restoring chemosensitivity.
Zheng Q, Tang J, Aicher A, Bou Kheir T, Sabanovic B, Ananthanarayanan P, Reina C, Chen M, Gu JM, He B, Alcala S, Behrens D, Lawlo RT, Scarpa A, Hidalgo M, Sainz B Jr, Sancho P, Heeschen C.
Zheng Q, et al. Among authors: sabanovic b.
J Exp Clin Cancer Res. 2023 Nov 28;42(1):323. doi: 10.1186/s13046-023-02883-y.
J Exp Clin Cancer Res. 2023.
PMID: 38012687
Free PMC article.